Advertisement

More Questions Raised About Dabigatran — Physician’s First Watch

Medical News |
July 24, 2014

More Questions Raised About Dabigatran

By Larry Husten

Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, FASAM

Relying on new evidence along with previously disclosed data, an investigation in the BMJ casts doubt on the reliability of data supporting the anticoagulant dabigatran (Pradaxa).

The most important new accusation is that Boehringer Ingelheim "failed to share with regulators information about the potential benefits of monitoring anticoagulant activity and adjusting the dose to make sure the drug is working as safely and effectively as possible. The company also withheld analyses that calculated how many major bleeds dose adjustment could prevent."

Editorialists write that the articles raise "serious questions" about dabigatran. They say they're concerned about "potentially higher than reported bleeding risk; the possibility of undertreating or overtreating with fixed doses, especially in older patients and patients with changing renal function; the unknown value of monitoring dabigatran levels and adjusting the dose; and the lack of a specific reversal agent."

The editorialists "suggest a shared decision that balances patients' tolerance of unknown risks, their tolerance of routine laboratory monitoring and dose adjustment, and their risk of stroke."

Boehringer Ingelheim strongly disputes the accusations.

Reader Comments (2)

Raul Altman, MD Physician, Hematology, Buenos Aires, Argentina

Not only with dabigatran. Therapeutic excesses can condition bleeding risk and therapeutic limitation can increase thrombotic risk, especially when short-acting drugs such as the new oral anticoagulants are used. Hence, it is imperative to establish an appropriate method for monitoring new oral anticoagulants, setting levels of safety and effectiveness through periodic dosage and monitoring of their anticoagulant effects

Gayle Roberts, MD Physician, Oncology, Tuscaloosa , AL

I am concerned about the warning that this can cause life threatening bleeding

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement